モンタナ州における乳がんの臨床試験
モンタナ州内の拠点で、乳がんに関する13件の研究が参加者を募集しています。
モンタナ州内の都市
公式研究テキスト（英語）
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
- Intermountain Healthcare, Billings
被験者募集中第3相
18歳〜100歳 · 全性別 · 2026/10/02更新 · NCT05827081Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Community Hospital of Anaconda, Anaconda
- Billings Clinic Cancer Center, Billings
- Bozeman Health Deaconess Hospital, Bozeman
- 他7件
被験者募集中観察研究健康なボランティア歓迎
40歳〜75歳 · 全性別 · 2026/10/02更新 · NCT05334069ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
- St. Vincent Regional Hospital - Cancer Centers of Montana, Billings
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/25更新 · NCT07007559Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
- Intermountain Health St. Vincent Regional Hospital - Cancer Centers of Montana ( Site 0003), Billings
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/10更新 · NCT06797635A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With Early-stage and Advanced HR+ Breast Cancer
- St. Vincent Frontier Cancer Center (SVFCC) - Billings (Frontier Cancer Center and Blood Institute), Billings
被験者募集中第1相
18歳〜55歳 · 女性 · 2026/09/09更新 · NCT07310420Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
- Community Hospital of Anaconda, Anaconda
- Billings Clinic Cancer Center, Billings
- Saint Vincent Frontier Cancer Center, Billings
- 他10件
被験者募集中第3相
18歳〜60歳 · 女性 · 2026/09/02更新 · NCT05879926Integrated Cancer Repository for Cancer Research
- Bozeman Health Deaconess Hospital, Bozeman
被験者募集中観察研究健康なボランティア歓迎
19歳〜110歳 · 全性別 · 2026/06/29更新 · NCT02012699Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
- SCL Health - Cancer Centers of Montana, Billings
被験者募集中第3相
18歳以上 · 全性別 · 2026/05/18更新 · NCT06757634De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
- Billings Clinic Cancer Center, Billings
- Bozeman Health Deaconess Hospital, Bozeman
- Benefis Sletten Cancer Institute, Great Falls
- 他1件
被験者募集中第3相
50歳〜70歳 · 全性別 · 2026/04/23更新 · NCT04852887Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
- Community Hospital of Anaconda, Anaconda
- Billings Clinic Cancer Center, Billings
- Montana Cancer Consortium NCORP, Billings
- 他5件
被験者募集中観察研究
18歳以上 · 全性別 · 2026/03/17更新 · NCT06418204Telehealth Exercise Program Evaluating Fatigue and Physical Function in Rural Cancer Survivors
- University of Montana, Missoula
被験者募集中第2相
18歳〜89歳 · 全性別 · 2026/02/05更新 · NCT07001241SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Billings
被験者募集中観察研究
全年齢 · 全性別 · 2025/10/28更新 · NCT03452774S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
- Benefis Healthcare- Sletten Cancer Institute, Great Falls
被験者募集中第3相
18歳以上 · 全性別 · 2025/10/08更新 · NCT03418961ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。